NCT05661448 Promoting Cognitive Health in Schizophrenia
| NCT ID | NCT05661448 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Douglas Mental Health University Institute |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 390 participants |
| Start Date | 2023-04-15 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 390 participants in total. It began in 2023-04-15 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to effectively implement virtually-delivered interventions in mental health institutions nationwide to improve the cognitive health of individuals living with schizophrenia. The main objectives are: * To determine the clinical effectiveness of two virtual cognitive health interventions (i.e., Action-Based Cognitive Remediation or MetaCognitive Training). * To evaluate our implementation strategy involving the virtual delivery of cognitive health interventions combined with a digital learning platform to train mental health practitioners. Participants will be assessed for the severity of symptoms, cognitive performance, and overall functioning before and after receiving the intervention. Qualitative interviews will also be conducted with participants and therapists to evaluate the implementation strategies.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of affective or non-affective psychosis or related disorder; * Follow-up and treatment by a clinician at one of the services mentioned above; * Participants symptomatically stable and capable of using the online platforms and participating in intervention groups, as judged by their primary clinicians (i.e., psychiatrist, case manager); * Participants must have access to a private space (i.e., a room where the participant can be alone) to ensure confidentiality for the group; * Participants must be able to nominate an emergency contact and to agree to allow researchers to contact their clinician and/or emergency services in the event of an emergency during study procedures. Exclusion Criteria: * Intellectual disability; * Hospitalization at the time of recruitment; * Inability to speak or read English or French; * High suicide risk as per evaluation.
Contact & Investigator
Martin Lepage
PRINCIPAL INVESTIGATOR
Douglas Mental Health University Institute
Frequently Asked Questions
Who can join the NCT05661448 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05661448 currently recruiting?
Yes, NCT05661448 is actively recruiting participants. Contact the research team at karyne.anselmo@douglas.mcgill.ca for enrollment information.
Where is the NCT05661448 trial being conducted?
This trial is being conducted at Vancouver, Canada, Kingston, Canada, Ottawa, Canada, Toronto, Canada and 1 additional location.
Who is sponsoring the NCT05661448 clinical trial?
NCT05661448 is sponsored by Douglas Mental Health University Institute. The principal investigator is Martin Lepage at Douglas Mental Health University Institute. The trial plans to enroll 390 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.